Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
3(33%)
Results Posted
50%(2 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_4
3
33%
Ph phase_2
3
33%
Ph not_applicable
1
11%
Ph phase_3
2
22%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Recruiting3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (33.3%)
Phase 32 (22.2%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

completed444%
recruiting333%
terminated222%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9